BELTSVILLE, Md. — January 28, 2026 — Leads & Copy — REPROCELL has commercially launched StemEdit, offering clinical gene editing services and new gene-edited iPSC product lines using OpenCRISPR-1™, an AI-designed genome editing system licensed from Profluent.
StemEdit combines REPROCELL’s clinical gene-editing technology and ready-to-use gene-edited iPSC lines. It integrates REPROCELL’s StemRNA™ Clinical iPSC Seed Clones with OpenCRISPR-1™-enabled engineering workflows, providing a GMP-aligned, traceable, and regulatory-ready platform.
OpenCRISPR-1™ is an AI-designed gene editor created using large language models trained on CRISPR-Cas datasets. Early reports suggest high editing efficiency, reduced off-target activity, and lower predicted immunogenicity in human cells, making it suitable for clinical and translational applications.
The new StemEdit services and cell lines are designed to support allogeneic off-the-shelf cell therapy development, offering enhanced targeting flexibility, improved safety profiles, and licensing-friendly alternatives to CRISPR-Cas systems. This aims to simplify intellectual property complexity and reduce commercial risk for therapeutic developers, enabling faster adoption. All products and services are delivered under GMP-aligned workflows, with quality control and documentation to support clinical translation and regulatory expectations.
REPROCELL’s CEO, Dr. Chikafumi Yokoyama, stated that the launch of StemEdit and incorporation of OpenCRISPR-1™ under an open-source license will provide customers with immediate access to next-generation gene editing technologies for clinical translation, scalability, and regulatory confidence.
REPROCELL USA Inc.’s CEO, Rama Modali, added that StemEdit marks a step forward for cell therapy development, combining AI-designed genome editing with StemRNA™ iPSC Seed clones to provide a faster, cleaner path from research to the clinic. This platform removes IP and scalability barriers, allowing partners to focus on bringing therapies to patients.
REPROCELL provides integrated stem cell, gene editing, molecular, and biorepository services from discovery through clinical development. Headquartered in Yokohama, Japan, with operations in the United States, Europe, and Asia, REPROCELL partners with academic, biotech, and pharmaceutical organizations.
Source: REPROCELL
